William J. Regan, SVP-Global Regulatory Strategy at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 5,000 shares at $2.71 ($14K) on 2013-03-15, disclosed to the SEC on 2013-03-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |